The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at
least rifampicin and isoniazid) represents a growing threat to public health and economic …

Tuberculosis (TB) remains a leading cause of death globally among infectious diseases that
has killed more numbers of people than any other infectious diseases. Animal models have …

There is urgent need for new drug regimens that more rapidly cure tuberculosis (TB).
Existing TB drugs and regimens vary in treatment-shortening activity, but the molecular basis …

Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III
trials: New technologies and innovative designs | PLOS Medicine Skip to main content …

Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most
concerning are the reports of multidrug drug resistance. Paradoxically, this global health …

Advances in clinical trial design: Weaving tomorrow’s TB treatments | PLOS Medicine Skip to
main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …

For many years, tuberculosis (TB) has been a major public health problem worldwide.
Advances for treatment and eradication have been very limited. Silymarin (Sm) is a natural …

After decades of limited progress, the development of novel anti-TB medicines was
revitalised at the start of the 21st century through new initiatives and investments. This has …

Tuberculosis lung lesions are complex and harbor heterogeneous microenvironments that
influence antibiotic effectiveness. Major strides have been made recently in understanding …